% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Awwad:167550,
      author       = {M. H. S. Awwad and A. Mahmoud and H. Bruns and H.
                      Echchannaoui$^*$ and K. Kriegsmann and R. Lutz and M.-S.
                      Raab$^*$ and U. Bertsch and M. Munder and A. Jauch and K.
                      Weisel and B. Maier and N. Weinhold and H. J. Salwender and
                      V. Eckstein and M. Hänel and R. Fenk and J. Dürig and B.
                      Brors$^*$ and A. Benner$^*$ and C. Müller-Tidow and H.
                      Goldschmidt and M. Hundemer},
      title        = {{S}elective elimination of immunosuppressive {T} cells in
                      patients with multiple myeloma.},
      journal      = {Leukemia},
      volume       = {35},
      number       = {9},
      issn         = {1476-5551},
      address      = {London},
      publisher    = {Springer Nature},
      reportid     = {DKFZ-2021-00415},
      pages        = {2602-2615},
      year         = {2021},
      note         = {2021 Sep;35(9):2602-2615},
      abstract     = {Elimination of suppressive T cells may enable and enhance
                      cancer immunotherapy. Here, we demonstrate that the cell
                      membrane protein SLAMF7 was highly expressed on
                      immunosuppressive CD8+CD28-CD57+ Tregs in multiple myeloma
                      (MM). SLAMF7 expression associated with T cell exhaustion
                      surface markers and exhaustion-related transcription factor
                      signatures. T cells from patients with a high frequency of
                      SLAMF7+CD8+ T cells exhibited decreased immunoreactivity
                      towards the MART-1aa26-35*A27L antigen. A monoclonal
                      anti-SLAMF7 antibody (elotuzumab) specifically depleted
                      SLAMF7+CD8+ T cells in vitro and in vivo via
                      macrophage-mediated antibody-dependent cellular phagocytosis
                      (ADCP). Anti-SLAMF7 treatment of MM patients depleted
                      suppressive T cells in peripheral blood. These data
                      highlight SLAMF7 as a marker for suppressive CD8+ Treg and
                      suggest that anti-SLAMF7 antibodies can be used to boost
                      anti-tumoral immune responses in cancer patients.},
      cin          = {FM01 / A360 / B330 / C060},
      ddc          = {610},
      cid          = {I:(DE-He78)FM01-20160331 / I:(DE-He78)A360-20160331 /
                      I:(DE-He78)B330-20160331 / I:(DE-He78)C060-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:33597728},
      doi          = {10.1038/s41375-021-01172-x},
      url          = {https://inrepo02.dkfz.de/record/167550},
}